This article is free to access.
Background: There is a paucity of contemporary data assessing the implications of atrial fibrillation (AF) on major adverse cardiovascular events (MACE) in patients with or at high-risk for atherosclerotic disease managed in routine practice. Hypothesis: We sought to evaluate the 4-year incidence of MACE in patients with or at risk of atherosclerotic disease in the presence of AF. Methods: Using US MarketScan data, we identified AF patients ≥45 years old with billing codes indicating established coronary artery disease, cerebrovascular disease, or peripheral artery disease or the presence of ≥3 risk factors for atherosclerotic disease from January 1, 2013 to December 31, 2013 with a minimum of 4-years of available follow-up. We calculated the 4-year incidence of MACE (cardiovascular death or hospitalization with a primary billing code for myocardial infarction or ischemic stroke). Patients were further stratified by CHA2DS2-VASc score and oral anticoagulation (OAC) use at baseline. Results: We identified 625,951 patients with 4-years of follow-up, of which 77,752 (12.4%) had comorbid AF. The median (25%, 75% range) CHA2DS2-VASc score was 4 (3, 5) and 64% of patients received an OAC at baseline. The incidence of MACE increased as CHA2DS2-VASc scores increased (P-interaction
Miao, B., Hernandez, A. V., Roman, Y. M., Alberts, M. J., Coleman, C. I., & Baker, W. L. (2020). Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation. Clinical Cardiology, 43(5), 524–531. https://doi.org/10.1002/clc.23344